

Brompton Global Healthcare Income & Growth ETF
Summary of Investment Portfolio as at September 30, 2020

Total Net Asset Value \$ 55,812,862

Portfolio Composition	% of Portfolio	% of Net Asset Value
North America		
United States		
Healthcare equipment	35.1%	35.8%
Biotechnology	12.3%	12.5%
Life sciences tools and services	10.5%	10.7%
Pharmaceuticals	10.2%	10.5%
Managed healthcare	5.0%	5.1%
Healthcare services	3.0%	3.0%
Healthcare technology	2.0%	2.0%
Healthcare supplies	1.9%	1.9%
Total North America	80.0%	81.5%
Europe		
Denmark		
Pharmaceuticals	3.5%	3.6%
France		
Pharmaceuticals	3.2%	3.2%
Germany		
Pharmaceuticals	1.9%	1.9%
Great Britain		
Pharmaceuticals	3.3%	3.3%
Ireland		
Healthcare equipment	3.7%	3.8%
Netherlands		
Healthcare equipment	1.5%	1.5%
Switzerland		
Pharmaceuticals	1.5%	1.5%
Total Europe	18.6%	18.8%
Cash and short-term investments	1.4%	1.4%
Total Investment Portfolio	100.0%	101.7%
Other net liabilities		(1.7%)
Total Net Asset Value		100.0%

Top 25 Holdings	% of Portfolio	% of Net Asset Value
Abbott Laboratories	4.6%	4.9%
Edwards Lifesciences Corp	4.0%	4.2%
Zoetis Inc	3.7%	3.9%
Steris plc	3.7%	3.8%
Agilent Technologies Inc	3.7%	3.8%
IDEXX Laboratories Inc	3.6%	3.6%
Novo Nordisk A/S	3.6%	3.6%
Danaher Corp	3.6%	3.6%
Hologic Inc	3.5%	3.6%
Thermo Fisher Scientific Inc	3.5%	3.6%
Intuitive Surgical Inc	3.5%	3.5%
Becton Dickinson and Co	3.5%	3.5%
Amgen Inc	3.3%	3.4%
UnitedHealth Group Inc	3.3%	3.4%
Eli Lilly and Co	3.3%	3.3%
AstraZeneca PLC	3.3%	3.3%
Abbvie Inc	3.2%	3.2%
Sanofi SA	3.2%	3.2%
Baxter International Inc	3.0%	3.0%
Quest Diagnostics Inc	3.0%	3.0%
Resmed Inc	2.7%	2.8%
Teladoc Health Inc	2.0%	2.0%
Boston Scientific Corp	1.9%	2.0%
Merck KGaA	1.9%	1.9%
West Pharmaceutical Services Inc	1.9%	1.9%
Total	80.5%	82.0%

The investment portfolio may change due to ongoing portfolio transactions of the investment fund. Quarterly updates are available on the Fund's website at www.bromptongroup.com within 60 days of each quarter end.